Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-DC Vaccine in Advanced Solid Tumors
NCT06682117Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of Neo-DCVac in solid tumor, sponsored by Fudan University. Primary endpoint: Adverse events at 28 days. Started Nov 2024; status: recruiting.
02
Drugs
Neo-DCVac
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06682117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682117.